BioSyngen

BioSyngen is a Singapore-based biotechnology startup founded in 2016 with a clear focus on developing first-in-class cell therapies targeting solid and liquid tumors. The company has made significant strides in its clinical stage, with its first-in-class products entering Phase I/II clinical trials for nasopharyngeal cancer, lymphoproliferative disease, and lung cancer, with Orphan Drug Designation (ODD) and Fast-Track designation. The company strategically positions itself at the intersection of public-private biopharma ecosystem, driving its international strategy from its global headquarters in Singapore and its clinical center in Guangzhou, China. It also focuses on enriching its pipeline with further IND submissions and collaborates for breakthroughs, especially in translational R&D and clinical development. BioSyngen is committed to playing a pivotal role in accelerating drug development from bench-to-bedside. It has set up a Translational Medicine Centre, a public-private partnership that connects stakeholders in R&D, Clinical Development, Hospitals, Pharma, Enterprises, and Venture Capital. The company also has GMP cell therapy manufacturing facilities in two key locations - in Singapore and Guangzhou, thus covering global needs. Notably, BioSyngen secured its last investment of CNY500.00M in a Venture Round investment on 21 October 2021, with the SCI Group as the investor. As the company continues to progress in its mission to offer better prospects for cancer patients, it remains an intriguing proposition for investment and partnership opportunities in the biotech industry. For more information, visit their website at www.biosyngen.com.